Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.16 USD | +0.42% | +7.67% | +6.87% |
05-20 | Barclays Adjusts Price Target on GoodRx to $10 From $9, Maintains Overweight Rating | MT |
05-17 | UBS Adjusts Price Target on GoodRx Holdings to $9 From $8, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.87% | 2.68B | |
+30.99% | 470B | |
+33.63% | 276B | |
+3.90% | 135B | |
+30.50% | 94.76B | |
+62.27% | 61.13B | |
+14.09% | 46.6B | |
+25.91% | 38.08B | |
-0.62% | 35.74B | |
+12.07% | 29.13B |
- Stock Market
- Equities
- GDRX Stock
- News GoodRx Holdings, Inc.
- BofA Securities Downgrades GoodRx Holdings to Underperform From Buy, Adjusts Price Target to $4.50 From $8